Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

Animesh Pardanani, MBBS, PhD, Ramy A. Abdelrahman, MBBCh, Christy Finke, BS, Terra L Lasho, PhD, Kebede Begna, MD, Aref Al-Kali, MD, William J. Hogan, MBChB, Mark R. Litzow, MD, Curtis A. Hanson, MD, Rhett Ketterling, MD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 3162.

https://doi.org/10.1182/blood.V124.21.3162.3162

Published: 2014

Journal Articles

Revised Cytogenetic Risk Stratification in Primary Myelofibrosis: A Mayo Clinic Study of 903 Patients

Ayalew Tefferi, MD, Emnet A Wassie, MD, Kebede Begna, MD, Christy Finke, BS, Alem A Belachew, Naseema Gangat, MD, Terra L Lasho, PhD, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Rhett Ketterling, MD

Blood (2014) 124 (21): 631.

https://doi.org/10.1182/blood.V124.21.631.631

Published: 2014

Journal Articles

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Ayalew Tefferi, MD, Betsy R. LaPlant, MS, Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Terra L Lasho, PhD, Darci Zblewski, CNP, Christy Finke, BS, Lauren Schimek, Adam Pettinger, Curtis A. Hanson, MD, Naseema Gangat, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 634.

https://doi.org/10.1182/blood.V124.21.634.634

Published: 2014

Journal Articles

Momelotinib Treatment-Associated Neuropathy: Prevalence, Risk Factors and Outcome in 100 Patients with Myelofibrosis

Ramy A. Abdelrahman, MBBCh, Kebede Begna, MD, Aref Al-Kali, MD, William J. Hogan, MBChB, Mark Litzow, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 1837.

https://doi.org/10.1182/blood.V124.21.1837.1837

Published: 2014

Journal Articles

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Animesh Pardanani, MBBS, PhD, Ramy A Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Terra L Lasho, MT, (ASCP), Christy Finke, BS, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4048.

https://doi.org/10.1182/blood.V122.21.4048.4048

Published: 2013

Journal Articles

Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide

Animesh Pardanani, MBBS, PhD, Ramy A. Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 4049.

https://doi.org/10.1182/blood.V122.21.4049.4049

Published: 2013

Journal Articles

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Meera Sridharan, MD, PhD, Aref Al-Kali, MD, Aneel A. Ashrani, MBBS, MSc, Kebede Begna, MD, Michelle Elliott, William J. Hogan, MBChB, Carl C. Hook, MD, Scott H. Kaufmann, MD, PhD, Louis Letendre, MD, Mark R. Litzow, MD, Mrinal M. Patnaik, MBBS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Alexandra Wolanskyj, MD, Rajiv K. Pruthi, MBBS

Blood (2013) 122 (21): 5000.

https://doi.org/10.1182/blood.V122.21.5000.5000

Published: 2013

Journal Articles

Real-World “myelodysplastic Syndrome-unclassifiable” and Its Comparison With “refractory Cytopenia With Multi-Lineage dysplasia” and “refractory anemia”

Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Naseema Gangat, MD, Biruk Mengistu, MD, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 1574.

https://doi.org/10.1182/blood.V122.21.1574.1574

Published: 2013

Journal Articles

Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia

Aysha K Alsahlawi, Hassan Alkhateeb, MD, Mrinal M. Patnaik, MBBS, Kebede Begna, MD, Michelle Elliott, MD, William Hogan, MD, Rhett P Ketterling, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2013) 122 (21): 1334.

https://doi.org/10.1182/blood.V122.21.1334.1334

Published: 2013

Journal Articles

Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival

Ramy A. Abdelrahman, MBBCh, Kebede Begna, MD, Darci Zblewski, RN, CNP, Aref Al-Kali, MD, Mrinal M. Patnaik, MBBS, William Hogan, MD, Ryan A Knudson, Rhett P Ketterling, Curtis A. Hanson, MD, Mark R. Litzow, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 2821.

https://doi.org/10.1182/blood.V122.21.2821.2821

Published: 2013

Journal Articles

Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence

Ayalew Tefferi, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Kebede Begna, MD, Mario Cazzola, Francisco Cervantes, MD, PhD, Konstanze Döhner, M.D., Heinz Gisslinger, MD, Vikas Gupta, MD, MRCP, FRCPath, Wang Li, C N Harrison, Jean-Jacques Kiladjian, Mary Frances McMullin, MD, MRCPath, Alessandro Rambaldi, MD, Gary J. Schiller, MD, FACP, Alessandro M Vannucchi, MD, Ruben A. Mesa, MD

Blood (2013) 122 (21): 394.

https://doi.org/10.1182/blood.V122.21.394.394

Published: 2013

Journal Articles

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Ayalew Tefferi, MD, Kebede Begna, MD, Rebecca R. Laborde, PhD, Mrinal M Patnaik, MBBS, Terra L Lasho, MT, (ASCP), Darci Zblewski, Christy Finke, BS, Lauren Schimek, Betsy R. LaPlant, Curtis A. Hanson, MD, Monic J. Stuart, MD, MPH, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 662.

https://doi.org/10.1182/blood.V122.21.662.662

Published: 2013

Journal Articles

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Animesh Pardanani, MBBS, PhD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, FRACP, PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Kebede Begna, MD, Hiroyuki Yoshitsugu, PhD, Toni Ann Gestone, PhD, Penny Phillips, PhD, Guan Xing, PhD, Gerson Peltz, MD, MPH, Matthew V Lorenzi, PhD, Leila Alland, MD, Adrian Woolfson, BM BCh, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 664.

https://doi.org/10.1182/blood.V122.21.664.664

Published: 2013

Journal Articles

Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Saad J. Sirop, MD, Aref Al-Kali, MD, Kebede Begna, MD, Naseema Gangat, MD, Louis Letendre, MD, Luis F. Porrata, MD, William J Hogan, MD, Mark R Litzow, MD, Mrinal M. Patnaik, MBBS, MD

Blood (2012) 120 (21): 1476.

https://doi.org/10.1182/blood.V120.21.1476.1476

Published: 2012

Journal Articles

Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS)

Naseema Gangat, MD, Mrinal M. Patnaik, MBBS, MD, Kebede Begna, MD, Taxiarchis Kourelius, MD, Ryan A Knudson, Rhett P Ketterling, MD, Janice M Hodnefield, MS, MT(ASCP), Curtis A Hanson, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD

Blood (2012) 120 (21): 423.

https://doi.org/10.1182/blood.V120.21.423.423

Published: 2012

Journal Articles

Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,

Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Daniel L. Van Dyke, Ph.D., Domenica Caramazza, Alessandro M. Vannucchi, MD, Enrica Morra, Mario Cazzola, Arturo Pereira, MD. PhD, Francisco Cervantes, MD, Francesco Passamonti, MD

Blood (2011) 118 (21): 3833.

https://doi.org/10.1182/blood.V118.21.3833.3833

Published: 2011

Journal Articles

IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,

Animesh Pardanani, MBBS, PhD, Christy Finke, BS, Terra L Lasho, MT, (ASCP), Aref Al-Kali, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3795.

https://doi.org/10.1182/blood.V118.21.3795.3795

Published: 2011

Journal Articles

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Animesh Pardanani, MBBS, PhD, Jason Gotlib, M.D., M.S., Vikas Gupta, MD, FRCP, FRCPath, Andrew W Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Mark R. Litzow, MD, William J Hogan, MBBCh, Kebede Begna, MD, Gregg Smith, PhD, MBA, Linda M Bavisotto, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3849.

https://doi.org/10.1182/blood.V118.21.3849.3849

Published: 2011

Journal Articles

Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials

Kebede Begna, MD, Animesh Pardanani, MBBS, PhD, Ruben A. Mesa, MD, William J Hogan, MBBCh, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 1759.

https://doi.org/10.1182/blood.V118.21.1759.1759

Published: 2011

Journal Articles

Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases

Ayalew Tefferi, MD, Naseema Gangat, MD, Rakhee Vaidya, MD, Kebede Begna, MD, Curtis A. Hanson, MD, Daniel L. Van Dyke, Ph.D., Domenica Caramazza, Animesh Pardanani, MBBS, PhD

Blood (2011) 118 (21): 2806.

https://doi.org/10.1182/blood.V118.21.2806.2806

Published: 2011

NARROW

Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients

Revised Cytogenetic Risk Stratification in Primary Myelofibrosis: A Mayo Clinic Study of 903 Patients

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Momelotinib Treatment-Associated Neuropathy: Prevalence, Risk Factors and Outcome in 100 Patients with Myelofibrosis

Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients

Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Real-World “myelodysplastic Syndrome-unclassifiable” and Its Comparison With “refractory Cytopenia With Multi-Lineage dysplasia” and “refractory anemia”

Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia

Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival

Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS)

Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,

IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials

Predictors of Greater Than 80% Two-Year Mortality in Primary Myelofibrosis: A Mayo Clinic Study of 884 Karyotypically-Annotated Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only